Trial Profile
A Cohort for Evaluation of Open-label PrEP Delivery Among Kenyan and South African Women: The POWER Cohort
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Dec 2021
Price :
$35
*
At a glance
- Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary)
- Indications HIV infections
- Focus Therapeutic Use
- Acronyms POWER
- 02 Dec 2021 Status changed from active, no longer recruiting to completed.
- 02 Nov 2020 Planned End Date changed from 1 Jul 2020 to 1 Jun 2021.
- 02 Nov 2020 Planned primary completion date changed from 1 Jul 2020 to 1 Jun 2021.